Substrates of human cytochromes P450 from families CYP1 and CYP2: analysis of enzyme selectivity and metabolism
- PMID: 15508429
- DOI: 10.1515/dmdi.2004.20.3.111
Substrates of human cytochromes P450 from families CYP1 and CYP2: analysis of enzyme selectivity and metabolism
Abstract
A compilation of information relating to substrate metabolism via human cytochromes P450 (CYP) from the CYP1 and CYP2 families is reported. The data presented include details of preferred sites of metabolism and Km values (usually for the expressed enzymes) for each reaction for selected substrates of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP2E1. Although other P450 databases are available, they do not provide such information as is collated here, and which can prove useful for comparing P450 substrate characteristics. This information can be employed in analysing the structural requirements for human P450 enzyme selectivity and for establishing various rules regarding preferred site of metabolism for selective P450 substrates. For example, in most cases it would appear that there is a set number of intervening 'heavy' atoms (atoms other than hydrogen) between sites of metabolism and key hydrogen bond acceptors (or donors) for human P450 substrates, with the number of intervening atoms being dependent upon the type of P450 involved.
Similar articles
-
Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes.Arch Biochem Biophys. 2003 Jan 1;409(1):32-44. doi: 10.1016/s0003-9861(02)00349-1. Arch Biochem Biophys. 2003. PMID: 12464242
-
Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.Drug Metab Dispos. 2003 Apr;31(4):439-46. doi: 10.1124/dmd.31.4.439. Drug Metab Dispos. 2003. PMID: 12642470
-
Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease.Drug Metab Dispos. 2009 Oct;37(10):2087-94. doi: 10.1124/dmd.109.027466. Epub 2009 Aug 3. Drug Metab Dispos. 2009. PMID: 19651758 Free PMC article.
-
How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?J Clin Pharm Ther. 2003 Jun;28(3):157-65. doi: 10.1046/j.1365-2710.2003.00486.x. J Clin Pharm Ther. 2003. PMID: 12795773 Review.
-
Progress in cytochrome P450 active site modeling.Arch Biochem Biophys. 2005 Jan 15;433(2):361-8. doi: 10.1016/j.abb.2004.08.026. Arch Biochem Biophys. 2005. PMID: 15581592 Review.
Cited by
-
Pharmacogenetics of analgesic drugs.Br J Pain. 2013 Nov;7(4):189-208. doi: 10.1177/2049463713507439. Br J Pain. 2013. PMID: 26516523 Free PMC article.
-
The chemical defensome: environmental sensing and response genes in the Strongylocentrotus purpuratus genome.Dev Biol. 2006 Dec 1;300(1):366-84. doi: 10.1016/j.ydbio.2006.08.066. Epub 2006 Sep 3. Dev Biol. 2006. PMID: 17097629 Free PMC article.
-
Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance.Front Genet. 2013 Mar 5;4:24. doi: 10.3389/fgene.2013.00024. eCollection 2013. Front Genet. 2013. PMID: 23467454 Free PMC article.
-
Liver-specific cytochrome P450 CYP2C22 is a direct target of retinoic acid and a retinoic acid-metabolizing enzyme in rat liver.J Lipid Res. 2010 Jul;51(7):1781-92. doi: 10.1194/jlr.M002840. Epub 2010 Feb 10. J Lipid Res. 2010. PMID: 20147703 Free PMC article.
-
Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs.Drug Metab Dispos. 2009 Mar;37(3):644-50. doi: 10.1124/dmd.108.023655. Epub 2008 Dec 12. Drug Metab Dispos. 2009. PMID: 19074527 Free PMC article.